# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aptose Biosciences shares are trading lower by 53.7% during Tuesday's session. The company announced it is going to delist ...
HC Wainwright & Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and raises the price ...
Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollme...
U.S. stock futures fell on Wednesday after scaling fresh records on Tuesday. The futures of all four benchmark indices were tra...